SLC5A2 and type 2 diabetes mellitus: A similar mortality benefit favoring SGLT-2 inhibitors was highlighted in the EMPA-REG OUTCOME trial, where empagliflozin significantly reduced cardiovascular and all-cause mortality in T2DM patients [19].